Awadhesh Kumar Singh, Anoop Misra, Ashok Kumar Das, Anish Behl, Ankit Srivastava, Arunachalam Paneerselvam, Balaji Chidambaram, Banshi Saboo, Bipin Sethi, Brij Mohan Makkar, Ganapathi Bantwal, Hemant Thacker, Jayant Panda, Jothydev Kesavadev, Krishna G Seshadri, Mangesh Tiwaskar, Minakshisundaram Shunmugavelu, Rakesh Sahay, Sambit Das, Sanjay Agarwal, Shehla Shaikh, Surendra Kumar Sharma, Sunil Gupta, Supratik Bhattacharyya, Viswanathan Mohan, Vijaya Kumar Gunupati
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been used for almost a decade and have proven to be effective not only in managing Type 2 diabetes (T2D), but their cardio and renal protective features make them very useful in managing patients with risk of multiple comorbidities. This systematic review was undertaken by the authors because there is no evidence currently available in India that has studied the suitability of SGLT2i as a first-line agent in patients newly diagnosed with T2D in India...
December 2023: Journal of the Association of Physicians of India